MedPath

Musli Thyropeutics Ltd.

Musli Thyropeutics Ltd. logo
🇮🇱Israel
Ownership
Private
Established
2011-01-01
Employees
1
Market Cap
-
Website
http://www.musli.co.il

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (100.0%)

Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients

Phase 2
Terminated
Conditions
Glioblastoma Multiforme (GBM)
Interventions
Drug: Combined T3 and Methimazole treatment
First Posted Date
2016-01-13
Last Posted Date
2018-03-22
Lead Sponsor
Musli Thyropeutics Ltd.
Target Recruit Count
3
Registration Number
NCT02654041
Locations
🇮🇱

Tel-Aviv Medical Center, Israel, Tel-Aviv, Israel

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.